Teladoc Health (TDOC) just announced a change in its legal leadership. Longtime Chief Legal Officer Adam Vandervoort plans to step down in early November, and current senior legal executive Jonathan Dorfman is set to take over.
At around US$6.09 per share, Teladoc Health has seen its 90 day share price return fall about 28%, and the 1 year total shareholder return decline roughly 26%. This suggests momentum has been fading even as management refreshes its legal leadership and continues to work through earlier business challenges.
Scan beyond Teladoc Health and compare this kind of pressured performance with 32 high quality undervalued stocks, which combine earnings power with balance sheet support.
Teladoc Health’s slump and the legal handover can be read two ways, as a verdict on the underlying business or a swing in sentiment around virtual care. Where does the current valuation actually point?
Most Popular Narrative: 59% Undervalued
On the narrative view, Teladoc Health’s fair value sits at $15.00, which is well above the last close at $6.09. That gap is what powers the current debate around whether this depressed share price reflects sentiment or fundamentals.
Wall Street continues to price TDOC as an unprofitable, cash-burning "growth trap" trading at <0.5x EV/Sales and ~5x EV/EBITDA.
In reality, Teladoc is a cash-generative healthcare utility with: 1. $750M+ in hard cash protecting the downside. 2. $130M to $170M in annual free cash flow. 3. An expanding insurance-reimbursed mental health model.
See why 3 investors see Teladoc Health as 59% undervalued.
Result: Fair Value of $15.00 (UNDERVALUED)
Still, Teladoc Health’s story can break if BetterHelp’s insurance shift compresses profitability or if rival telehealth platforms capture more employer and health plan demand.
Find out about the key risks to this Teladoc Health narrative.
Next Steps
Mixed messages around Teladoc Health can either freeze you or push you to check the figures yourself and move with intent. To weigh the trade off between the concerns and the potential upside, review the 3 key rewards and 2 important warning signs.
Looking for more Teladoc Health sized opportunities?
If Teladoc Health has you thinking harder about where risk and reward really line up, do not stop here. Use the Simply Wall Street Screener to stress test ideas, compare quality, and spot gaps in your portfolio before someone else does.
- Target resilient returns by scanning companies that show fewer red flags and steadier fundamentals through the 30 resilient stocks with low risk scores.
- Hunt for potential mispriced quality by checking stocks that combine earnings support with attractive pricing using the 32 high quality undervalued stocks.
- Round out your watchlist with businesses that pair sound balance sheets with robust fundamentals through the list of solid balance sheet and fundamentals (24 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com